Stock Price Prediction

TXMD stock is currently trading around $1.70, with recent insider buying by a director signaling confidence despite a Q2 2024 loss of $0.09 per share. Bulls argue that the stock is undervalued due to its royalty-based pharmaceutical model, which provides stable income streams. A potential price target of $2.50 is suggested, driven by insider optimism and improving market sentiment.

TXMD stock is bearish due to weak fundamentals and poor financial performance. The stock recently reported a Q2 2024 loss of $0.09 per share and revenue of only $234,000, reflecting limited growth potential. With its current price near $1.70, further downside is likely unless significant operational improvements occur.